General News Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Reach Topline Data from KALAHARI Trial This Year EN November 16, 2023
General News Oxurion Receives EUR 1.5 Million under Amended Atlas Funding Program; Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial EN October 25, 2023
General News Oxurion Receives First EUR 1 Million under Amended Atlas Funding Program EN September 18, 2023
General News Oxurion Receives Funding of EUR One Million under Atlas Special Opportunities LLC (Atlas) Funding Program EN August 11, 2023
General News Oxurion Receives Upfront Payment of $400,000 Following Oncurious Asset License by VIB EN July 25, 2023
General News Oxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the Funding Program with Atlas Special Opportunities LLC EN June 15, 2023
General News Oxurion Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema EN June 12, 2023
General News Regulated Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema EN May 25, 2023
General News Oxurion Issues EUR 2.0 million in Bonds for Tranche 2 of the Funding Program with Atlas Special Opportunities LLC EN May 22, 2023
General News Regulated Oxurion Announces Results of the Annual Shareholders’ Meeting of 2 May 2023 EN May 15, 2023
General News Oxurion Issues EUR 2.0 million in Bonds for Tranche 1 (B) of the Funding Program with Atlas Special Opportunities LLC EN April 27, 2023
General News Oxurion Issues EUR 2.8 million in Bonds for Tranche 1 (A) of Funding Program with Atlas Special Opportunities LL EN March 20, 2023
General News Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema and Announces Board Changes EN March 14, 2023
General News Regulated Oxurion Announces Subscription Agreement with Atlas Providing the Company with Up To €20 Million in Funding EN March 2, 2023
General News Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Program EN January 27, 2023
General News Regulated Oxurion Announces Second Amendment to Negma Funding Program EN January 25, 2023
